Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market. The offering consists of 2.4 million common shares at US$6.25 per share, with expected gross proceeds of approximately US$15 million, excluding any exercise of the underwriter’s option to purchase up to an additional 360,000 shares. Joseph Gunnar & Co. LLC is acting as sole book-running manager for the offering, and trading on Nasdaq is expected to begin May 20, 2026, under the symbol OPTH.
The company intends to use the net proceeds to scale production and distribution of its psychedelic drug products, support market expansion including into the United States, and fund sales growth, working capital, and operating expenses. Optimi also confirmed the effectiveness of its previously announced 1-for-30 share consolidation, resulting in approximately 3.2 million common shares outstanding prior to the offering, subject to rounding and any additional issuances.
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
This offering marks a significant milestone for Optimi as it transitions to a major U.S. exchange, providing increased visibility and access to capital markets. The funds raised will be pivotal in expanding the company’s manufacturing capabilities and distribution network, particularly in the U.S. market, which is increasingly opening up to psychedelic therapies. For the industry, this move signals growing investor confidence in psychedelic medicine and the potential for these treatments to address the mental health crisis. The uplisting to Nasdaq could also pave the way for other psychedelic companies to follow suit, potentially accelerating the sector's legitimacy and growth.
For more information, visit the company's website at https://www.optimi.net/.
